1
项与 Super NK cell(Hangzhou Qihan Biotech) 相关的临床试验 / Not yet recruiting临床1期IIT Phase I Study to Evaluate the Safety and Efficacy of NK Cell Therapy in Acute Myeloid Leukemia (AML).
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of iPSC NK cells in patients with relapsed/refractory AML or AML Minimal Residual Disease (MRD).
100 项与 Super NK cell(Hangzhou Qihan Biotech) 相关的临床结果
100 项与 Super NK cell(Hangzhou Qihan Biotech) 相关的转化医学
100 项与 Super NK cell(Hangzhou Qihan Biotech) 相关的专利(医药)
100 项与 Super NK cell(Hangzhou Qihan Biotech) 相关的药物交易